Brokerage house Kotak Securities has shared a positive outlook on Godrej Agrovet and Narayana Health, assigning new fair values to both. The report highlights Godrej Agrovet’s oil palm business as a key value driver, while noting Narayana Health’s robust hospital performance despite short-term insurance headwinds.
Kotak Securities has released updated research covering Godrej Agrovet and Narayana Health, maintaining a constructive view on both companies. The brokerage has assigned a fair value of ₹1,010 to Godrej Agrovet and ₹2,350 to Narayana Health, pointing to their respective core business strengths as reasons for the optimism.
Godrej Agrovet and the Oil Palm Thesis
The brokerage identifies Godrej Agrovet’s oil palm segment as the primary engine for future growth. The company operates about 80,000 hectares under cultivation and remains the largest domestic producer of crude palm oil and palm kernel oil. As these plantations reach maturity, the company is expected to see higher fresh fruit bunch arrivals, which could boost volume growth without a proportional increase in costs.
Financial efficiency has also been a focal point, with the company’s return on capital employed reaching 20% in FY26. Beyond oil palm, the company's broader portfolio is seeing mixed results. The animal nutrition segment is reporting healthy growth, and Astec LifeSciences has shifted to an EBITDA-positive position. However, the crop care segment remains a point of caution, though the company is working to gain traction with newer products. Investors tracking Godrej Agrovet may monitor the company’s upcoming series of analyst and investor meetings, scheduled between September 8 and September 18, 2026, for further management insights on these operational shifts.
Narayana Health’s Hospital Growth vs. Insurance Drag
For Narayana Health, the core hospital business is driving the brokerage's positive view. Indian hospitals reported a strong 39% year-on-year EBITDA growth in the first quarter of fiscal year 2027, following a solid multi-year growth trend.
Despite this, the company faces near-term pressure from its insurance vertical. Losses in this segment widened in the first quarter of fiscal 2027, largely due to increased exposure to group policies written in the previous year. The management is currently attempting to rebalance the portfolio by shifting toward retail business, with expectations that losses will decrease significantly by fiscal year 2028.
Additional growth avenues for Narayana Health include its stable operations in the Cayman Islands and the recently acquired Practice Plus Group in the UK. While margins in the UK business are currently lower than in the domestic segment, the company aims to improve profitability through better payor mix and operational efficiencies. The path toward breakeven in the insurance vertical and the integration of the UK business remain key areas for investors to monitor in the coming quarters.